Wearable sensor data combined with machine learning predicts fall risk in Parkinson’s patients, enhancing preventive care and clinical outcomes over five years.
On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson’s disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently lacking effective cognitive therapies. Parkinson’s disease is a neurological disorder primarily k
Michael J. Fox has reportedly broken more bones than his own stuntman, Charlie Croughwell.Fox, who was diagnosed with Parkinson’s disease in 1991, has faced increasing physical challenges.Speaking with Metro, Croughwell, who…
Russian President Vladimir Putin’s uncontrollable leg twitching during a public speech in Kazakhstan has reignited rumors about his health, with speculation focusing on Parkinson’s disease or another neurological condition.